(-)-Dihydroquinine

326.43

326.43

208-334-0

31J3Q51T6L

C - Cardiovascular system|M - Musculo-skeletal system

2933990090

45.6

3.1

1.2±0.1 g/cm3

172.5 °C

498.4°C at 760 mmHg

255.2±24.6 °C

1.626

99.99mg/L(20 ºC)

D18 -142° (alc); D20 -236° (c = 0.82 in 0.1N H2SO4)

III

6.1(b)

1544

3

36/37/38

26-36

Xi

P261-P305 + P351 + P338

H315-H319-H335

|Warning|H302 (97.5%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P312, P304+P340, P312, P322, P330, P363, and P501|Aggregated GHS information provided by 40 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)|Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)

dihydroquinidine